What's Happening?
The Broadway revival of 'Every Brilliant Thing,' featuring Daniel Radcliffe and soon to star Mariska Hargitay, has successfully recouped its $5.75 million capitalization. The play, which began previews
at the Hudson Theatre on February 21 and officially opened on March 12, has been a top-grossing production. It recently received Tony Award nominations for Best Revival of a Play and Best Leading Actor in a Play for Radcliffe. The production will extend its limited engagement through June 28, with Hargitay joining the cast on May 26.
Why It's Important?
The financial success of 'Every Brilliant Thing' highlights the viability of revivals in Broadway's competitive landscape. The play's ability to recoup its investment underscores the potential profitability of well-executed revivals, especially those featuring popular actors like Radcliffe. This success may encourage producers to invest in similar projects, contributing to the diversity and richness of Broadway offerings. Additionally, the play's themes of hope and resilience resonate with audiences, potentially increasing its cultural impact.
What's Next?
With the extension of its run, 'Every Brilliant Thing' will continue to attract audiences, potentially increasing its profitability and influence. The addition of Mariska Hargitay to the cast may draw new viewers, further boosting ticket sales. The play's performance during the extended run will likely inform future decisions about revivals and casting strategies on Broadway.
